Ahmet Taskesen

Ahmet Taskesen

Auto-generated profile, based on publicly available information

Ahmet Taskesen

Faculty of Medicine, Department of Neurosurgery, Düzce University, Düzce, Turkey

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2025 in Metabolic Brain Disease
Verified
Journal Article
Closed access
PDF file
MKMustafa Kilic
Mustafa Kilic
CHCeyhan Hacıoğlu
Ceyhan Hacıoğlu
STSibel Tuncer
Sibel Tuncer
ATAhmet Taskesen
Ahmet Taskesen
CTCengiz Tuncer
Cengiz Tuncer

28 April 2026 in Molecular and Cellular Biochemistry
Verified
Journal Article
Open access
ATAhmet Taskesen
Ahmet Taskesen
CHCeyhan Hacıoğlu
Ceyhan Hacıoğlu
STSibel Tuncer
Sibel Tuncer
GKGüven Kilic
Güven Kilic
CTCengiz Tuncer
Cengiz Tuncer
Microglial activation is a central mediator of neuroinflammatory and neurodegenerative processes. Growing evidence indicates that dysregulated lipid metabolism and ferroptosis drive microglial dysfunction, yet pharmacological interventions targeting these interconnected pathways remain scarce. Fenofibrate is well-documented for its anti-inflammatory and antioxidant effects; nevertheless, its influence on microglial lipid metabolism and ferroptotic signaling remains unexplored. The present study was designed to examine the effects of fenofibrate on lipid remodeling, oxidative stress, and ferroptosis in human HMC3 microglia activated with lipopolysaccharide (LPS) and interferon-γ (IFN-γ). HMC3 cells were pre-treated with fenofibrate followed by inflammatory activation. Cell viability, cytokine secretion, oxidative stress, lipid droplet (LD) accumulation, and ferroptosis-associated markers were analyzed by ELISA, fluorescence imaging, qRT-PCR, and Western blotting. Fenofibrate decreased the production of TNF-α, IL-1β, and IL-6, restored mitochondrial membrane potential, and suppressed ROS and malondialdehyde (MDA) generation while increasing intracellular glutathione (GSH). The treatment markedly decreased LD accumulation by downregulating the lipid metabolism–related enzymes PLIN2, DGAT1, and GPAT4. Functional assays demonstrated enhanced fatty acid oxidation and restored lipolysis, directly confirming reprogrammed lipid catabolism. Moreover, fenofibrate attenuated ferroptotic stress, evidenced by reduced intracellular Fe²⁺ levels, decreased ACSL4 expression, and significant increase of the ferroptosis-protective enzyme GPX4. These molecular changes were accompanied by improved cell survival and decreased oxidative damage, suggesting that fenofibrate may partially modulate metabolic and and redox balance in activated microglia under in vitro conditions. In conclusion, these findings suggest that fenofibrate may exert protective effects by modulating lipid metabolism and suppressing ferroptosis-related pathways in activated microglia.

12 February 2026 in European Spine Journal
Verified
Journal Article
Open access
PDF file
CTCengiz Tuncer
Cengiz Tuncer
RDRabia Tuğba Durdubaş
Rabia Tuğba Durdubaş
VUVeysel Uludağ
Veysel Uludağ
GKGüven Kilic
Güven Kilic
ATAhmet Taşkesen
Ahmet Taşkesen
Background: The integration of AI in healthcare, particularly in clinical decision-making, has shown promising results. This study focuses on evaluating the performance of GPT-4 and GPT-3.5, two advanced AI models, in the context of spinal neurosurgery and physiotherapy, areas that require precise and dynamic decision-making. Methods: We conducted a prospective, observational study with 64 participants, including neurosurgeons and physiotherapists, who evaluated AI-generated responses for 10 detailed clinical scenarios. The assessment criteria included diagnostic accuracy, treatment suitability, surgical technique detail, and rehabilitation planning. Each scenario was meticulously crafted to reflect common yet complex clinical situations. Results: The study revealed that the GPT-4 consistently outperformed the GPT-3.5 across all the evaluated criteria, with the most significant differences observed in treatment suitability and rehabilitation planning. Statistical analyses, including paired t tests and ANOVA, confirmed the superiority of the GPT-4, highlighting its advanced language processing capabilities and broader medical knowledge base. Reliability analyses further supported these findings. Cronbach’s alpha values indicated moderate internal consistency for GPT-4 (α = 0.344) and lower consistency for GPT-3.5 (α = 0.133). Additionally, Cohen’s Kappa values demonstrated moderate agreement for GPT-4 (κ = 0.65) and fair agreement for GPT-3.5 (κ = 0.48), further validating the reliability of the participants’ evaluations. Conclusions: While the GPT-4 has significant potential as a clinical decision support tool, especially in complex and multidisciplinary fields such as spinal neurosurgery and physiotherapy, its recommendations should be carefully integrated with clinical expertise. Further research is essential to enhance its application and ensure that AI can effectively support dynamic medical environments.

25 July 2026 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
ATAhmet Taskesen
Ahmet Taskesen
CHCeyhan Hacıoğlu
Ceyhan Hacıoğlu
Glioblastoma (GBM) exhibits profound metabolic plasticity and resistance to conventional therapies, partly driven by mitochondrial adaptability and stress response mechanisms. ONC212, a second‐generation imipridone, targets mitochondrial proteostasis, yet determinants of tumour sensitivity remain unclear. This study aimed to investigate whether ATP‐sensitive potassium (KATP) channel expression modulates ONC212‐induced mitochondrial dysfunction and integrated stress response (ISR) activation in GBM. Human GBM lines (U87, U251, T98G) and non‐malignant SVG p12 astrocytes received ONC212 (0.5–80 μM) for 12–48 h. Viability was assessed by CCK‐8. KATP subunit expression (Kir6.2, SUR1, CCDC51) was quantified by qRT‐PCR and western blot. Mitochondrial ROS quantification, oxygen consumption rate (Seahorse XF), PERK/ATF4/CHOP activation (western blot, immunofluorescence) and apoptosis (caspase‐3/7) were evaluated. KATP was modulated pharmacologically (glibenclamide, diazoxide) and via KCNJ11 (Kir6.2) siRNA. ONC212 induced time‐dependent and tumour‐selective cytotoxicity, with highest sensitivity observed in KATP‐high U87 cells. Treatment significantly increased mitochondrial ROS, impaired oxidative phosphorylation and reduced ATP/ADP ratios, indicating bioenergetic collapse. Concurrently, ONC212 robustly activated the PERK/eIF2α/ATF4/CHOP axis and promoted ATF4 nuclear translocation. PERK inhibition attenuated both stress signalling and cytotoxicity, confirming ISR dependency. KATP inhibition enhanced ONC212‐induced mitochondrial dysfunction, ISR activation and apoptosis, whereas KATP activation exerted protective effects. Importantly, KCNJ11 silencing markedly potentiated ONC212 sensitivity, amplifying ROS production, mitochondrial impairment and caspase‐dependent apoptosis. KATP channel expression may regulate ONC212 responsiveness in GBM by modulating mitochondrial stress and ISR signalling. Targeting KATP channels may enhance imipridone efficacy and represents a promising strategy for metabolically guided GBM therapy.